OCD thrives on doubt, and a new book argues that psilocybin may confront that fear at its source.

In How to Not Know, Simone Stolzoff examines whether psychedelic treatment could help people living with obsessive-compulsive disorder, a condition often described as the doubting disorder. The central idea turns on uncertainty: OCD can lock people into repetitive thoughts and rituals meant to create certainty, while psilocybin may push the mind toward a different relationship with the unknown.

The book arrives as interest in psychedelic medicine expands beyond niche research circles and into mainstream conversations about mental health. Reports indicate researchers, clinicians, and patients continue to weigh whether substances once pushed to the margins might offer relief where standard approaches fall short. In that context, Stolzoff’s work appears to focus less on hype and more on a harder question: what happens when treatment does not eliminate uncertainty, but teaches people to live with it.

OCD feeds on the need to know, and the book asks whether psilocybin can weaken that need enough for people to break the cycle.

Key Facts

  • Simone Stolzoff’s new book is titled How to Not Know.
  • The book explores psilocybin as a possible treatment path for OCD.
  • OCD is described colloquially as the doubting disorder.
  • The discussion centers on whether psychedelic therapy can change how patients handle uncertainty.

That framing matters because it shifts the conversation away from miracle-cure narratives. OCD does not simply produce unwanted thoughts; it can drive a punishing loop of checking, reassurance-seeking, and mental review. Any treatment that targets the underlying demand for certainty would speak to the disorder’s core mechanics, not just its visible symptoms. Sources suggest this is where the book tries to make its case, connecting a deeply human struggle with a fast-moving field of science and culture.

What comes next will depend on how readers, clinicians, and researchers respond to this growing body of interest in psychedelic therapy. The stakes reach beyond one book or one drug: they touch a broader debate over how mental health care should treat suffering rooted in fear, control, and uncertainty. If psilocybin has a role in that future, it will matter not because it promises easy answers, but because it may help people endure life without needing every answer first.